| This week's sponsor is TD2. | |  | |
Today's Rundown - Biotech stocks fail to lift on so-so J.P. Morgan conference's first day
- In it for the long haul: A chat with Barry Greene
- After $270M round, BioNTech pens TCR pact with Scancell
- [Sponsored] INNOVATION BY DESIGN
- BerGenBio’s AXL inhibitor clears early efficacy test in NSCLC
- BioClin Therapeutics hires Gilead blood cancer R&D exec
- Datavant integrates 150 data sets, teams with Duke, G3, Verge Genomics
- FierceBiotech’s #JPM18 live blog: Alnylam, biotech stocks, BioNTech on a roll and more
- JPM need-to-know: J&J talks deal outlook, Teva chief ID's root of cost cuts, Allergan goes for reassurance, Vertex eyes M&A, and more
Featured Story | | | Tuesday, January 9, 2018 Last year, things were pretty quiet out of the J.P. Morgan Healthcare Conference: few deals, few major updates. That seemed to set the tone for much of the year, at least on the M&A front. |
|
|
| This week's sponsor is Veeva. | |  | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
Top Stories Tuesday, January 9, 2018 Alnylam President Barry Greene discusses the retooled Sanofi deal, Alnylam's transition to a commercial-stage company and what's on the horizon in 2018. Tuesday, January 9, 2018 BioNTech has followed up on its $270 million megaround by striking a deal with Scancell. The alliance gives BioNTech the chance to work with Scancell to discover and characterize T cell receptors (TCRs) and an option to form a license agreement covering the resulting therapeutics. Monday, January 8, 2018 Astellas, like many of our industry peers, prioritizes innovation. What sets Astellas apart, however, is how we function at the intersection where our “Science First” approach meets the flexibility we’ve built into our innovation infrastructure. Tuesday, January 9, 2018 BerGenBio has brought cancer drug BGB324 through an early efficacy assessment. The study linked the AXL inhibitor to a 33% disease control rate in non-small cell lung cancer (NSCLC) patients who had previously progressed following treatment with an EGFR inhibitor. Tuesday, January 9, 2018 Nearly a year after closing a second funding round, cancer biotech BioClin has nabbed Esteban (Steve) Abella, M.D., as its new chief medical officer. Tuesday, January 9, 2018 Aimed at helping drug development by improving the design and interpretation of clinical trials though data, Roivant Sciences’ Datavant is quickly expanding its database and has formed a series of partnerships with researchers. Tuesday, January 9, 2018 Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates. Monday, January 8, 2018 As J.P. Morgan Healthcare Conference attendees trooped through pouring rain and searched for the elusive taxi or Uber ride, biopharma CEOs talked tax reform, M&A and new data, some of it not so positive (see Axovant, for starters). Here's a full agenda of updates from Merck, Allergan, Teva and more. | This week's sponsor is Protea Biosciences. | | Protea's “BIOPHARMA” Assets Available For Sale in Morgantown, WV (Ch. 11 Debtor) - Cancer-Diagnostic Protocols, Lab EQ, & Licenses ($1.15MM Min)
- Stalking Horse Bid at $1.0MM Already Filed; Sale Hearing Date 01/24/18
- Small Molecule Analytics Business, EQ, & Cust. AR + $75.0MM NOLs ($1.0MM Min)
All assets to be sold via 363-Sale Auctions (No. Distr. of WV BK Court - Case: 17-1200) Bids are due by January 18, 2018 (Unless Extended) Contact: Jack Teitz, CRO for Additional Information: 412-855-7625 |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Seton Hall Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics. Sponsored by: Agilent This Agilent intact protein analysis includes: Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. |
|
